Erenumab Human monoclonal antibody targeting calcitonin gene-related peptide (CGRP) receptor Prevention of episodic and chronic migraine

摘要

There is a significant unmet need for new preventive treatments for migraine. The prominent role of calcitonin generelated peptide (CGRP) in the pathophysiology of migraine has stimulated the development of anti-CGRP therapeutics, including erenumab, a human monoclonal antibody targeting the canonical CGRP receptor. Erenumab has successfully transitioned from preclinical characterization and first-in- human-enabling toxicity studies to phase I-III clinical trials, including proof-of-concept dose-finding and large, placebocontrolled, double-blind trials in patients with episodic and chronic migraine. Results from the erenumab clinical trial program have demonstrated consistent, statistically significant and clinically meaningful efficacy with once-monthly 70- and 140-mg subcutaneous dosing. In addition, erenumab has shown a safety profile comparable to that of placebo. By targeting a pathophysiologically relevant receptor, erenumab has the potential to shift the treatment paradigm for migraine prevention toward a mechanism-specific approach.